NISCAIR Online Periodicals Repository

NISCAIR ONLINE PERIODICALS REPOSITORY (NOPR)  >
NISCAIR PUBLICATIONS >
Research Journals >
Indian Journal of Experimental Biology (IJEB) >
IJEB Vol.48 [2010] >
IJEB Vol.48(06) [June 2010] >


Title: Effect of preferential cyclooxygenase-2 (COX-2) inhibitor against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: Behavioral, biochemical and histological evidences
Authors: Gupta, Amit
Dhir, Ashish
Kumar, Anil
Kulkarni, S K
Keywords: Cyclooxygenase
1-methyl-4-phenyl-1,2,3,6-tertahydropyridine
Nimesulide
Neuroprotection
Oxidative stress
Parkinson’s disease
Issue Date: Jun-2010
Publisher: CSIR
Abstract: Cyclooxygenase (COX) isoenzyme is known to play an important role in the pathophysiology of Parkinson’s disease. The present study evaluated the neuroprotective effect of nimesulide, a preferential COX-2-inhibitor against 1-methyl-4-phenyl-1,2,3,6-tertahydropyridine (MPTP)-model of Parkinson’s disease. Intrastriatal administration of MPTP (32 μmol in 2 μl) produced a significant decrease in the locomotor activity. Biochemical investigation of striatal region revealed a significant enhancement in the oxidative stress as evidenced by increased lipid peroxidation levels, nitrite levels and myeloperoxidase activity along with depleted antioxidant pool (reduced glutathione and superoxide dismutase levels) and reduced redox (GSH/GSSG) ratio. MPTP administration also showed significant mitochondrial complex-I inhibition and reduction in the mitochondrial viability. Histological examination of the MPTP-treated brain sections revealed alteration in the histo-architecture as well as undifferentiated bodies of varying contour and lesions. Chronic administration of nimesulide (5 or 10 mg/kg, po) for 12 days, significantly reversed the behavioral, biochemical, mitochondrial and histological alterations induced by MPTP. In conclusion, the findings of the present study implicate the possible neuroprotective potential of nimesulide in MPTP-treated rats and thus highlight the therapeutic potential of COX-inhibitors in treatment of Parkinson’s disease.
Page(s): 577-585
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Source:IJEB Vol.48(06) [June 2010]

Files in This Item:

File Description SizeFormat
IJEB 48(6) 577-585.pdf237.8 kBAdobe PDFView/Open
 Current Page Visits: 653 
Recommend this item

 

National Knowledge Resources Consortium |  NISCAIR Website |  Contact us |  Feedback

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.

CC License Except where otherwise noted, the Articles on this site are licensed under Creative Commons License: CC Attribution-Noncommercial-No Derivative Works 2.5 India

Copyright © 2012 The Council of Scientific and Industrial Research, New Delhi. All rights reserved.

Powered by DSpace Copyright © 2002-2007 MIT and Hewlett-Packard | Compliant to OAI-PMH V 2.0

Home Page Total Visits: 585750 since 06-Feb-2009  Last updated on 18-Sep-2014Webmaster: nopr@niscair.res.in